Montelukast, an asthma drug, can bind to and block a crucial SARS-CoV-2 protein. This discovery sets the stage for a new class of antiviral drugs, designed to target and interfere with the virus' immunosuppressive tactics.
Subscribe to:
Post Comments (Atom)
-
Welcome to the weekly edition of Healthcare IT Today Bonus Features . This article will be a weekly roundup of interesting stories, product ...
-
The following is a guest article by Ladd Wiley, Senior Vice President for Global Corporate Affairs, Public Policy, and Advocacy at Epic , ...
-
Robert Connely of Pega says patching legacy systems will give way to true health IT modernization, a security breakthrough will lead artific...
No comments:
Post a Comment